203 related articles for article (PubMed ID: 35070976)
1. Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.
Fernández O; Lázaro-Quintela M; Crespo G; Soto de Prado D; Pinto Á; Basterretxea L; Gómez de Liaño A; Etxaniz O; Blasco S; Gabás-Rivera C; Aceituno S; Palomar V; Polanco-Sánchez C
Front Oncol; 2021; 11():773366. PubMed ID: 35070976
[TBL] [Abstract][Full Text] [Related]
2. How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China.
Zhang M; He X; Wu J; Wang X; Jiang Q; Xie F
Value Health; 2022 Oct; 25(10):1768-1777. PubMed ID: 35710892
[TBL] [Abstract][Full Text] [Related]
3. Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists' and Urologists' Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries.
Panattoni L; Kearney M; Land N; Flottemesch T; Sullivan P; Kirker M; Bharmal M; Hauber B
Pharmacoeconomics; 2024 Mar; ():. PubMed ID: 38472738
[TBL] [Abstract][Full Text] [Related]
4. Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study.
Boqué C; Abad MR; Agustín MJ; García-Goñi M; Moreno C; Gabás-Rivera C; Granados E; Castro-Gómez A; Pardo C; Lizán L
J Geriatr Oncol; 2020 Jan; 11(1):24-30. PubMed ID: 30954406
[TBL] [Abstract][Full Text] [Related]
5. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Shinde R; Basurto E; Joseph RW
Patient Prefer Adherence; 2017; 11():1389-1399. PubMed ID: 28860722
[TBL] [Abstract][Full Text] [Related]
6. Patient versus physician preferences for lipid-lowering drug therapy: A discrete choice experiment.
Zhang L; Chen J; Cao Z; Zhang M; Ma R; Zhang P; Yao G; Li X
Health Expect; 2024 Apr; 27(2):e14043. PubMed ID: 38590082
[TBL] [Abstract][Full Text] [Related]
7. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
[TBL] [Abstract][Full Text] [Related]
8. What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis.
Díaz-Torné C; Urruticoechea-Arana A; Ivorra-Cortés J; Díaz S; Dilla T; Sacristán JA; Inciarte-Mundo J; Comellas M; Prades M; Lizán L
Adv Ther; 2020 Apr; 37(4):1479-1495. PubMed ID: 32088860
[TBL] [Abstract][Full Text] [Related]
9. Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients.
Grivas P; Veeranki P; Chiu K; Pawar V; Chang J; Bharmal M
Future Oncol; 2023 Feb; 19(5):369-383. PubMed ID: 36876486
[TBL] [Abstract][Full Text] [Related]
10. Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China.
Sun H; Wang H; Xu N; Li J; Shi J; Zhou N; Ni M; Hu X; Chen Y
Patient Prefer Adherence; 2019; 13():1701-1709. PubMed ID: 31631985
[TBL] [Abstract][Full Text] [Related]
11. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
Stone RL; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Ritz S; Mulvihill E; Monberg M; Szamreta EA; Amin S; McLaurin K
Future Oncol; 2022 Feb; 18(4):491-503. PubMed ID: 34875854
[TBL] [Abstract][Full Text] [Related]
12. Preferences and Willingness to Pay for Medication in Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment.
Ding R; Shao R; Zhang L; Yan J
Patient; 2024 Jan; 17(1):97-108. PubMed ID: 38030868
[TBL] [Abstract][Full Text] [Related]
13. Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain.
Martinón-Torres F; de Miguel ÁG; Ruiz-Contreras J; Vallejo-Aparicio LA; García A; Gonzalez-Inchausti MC; de Gomensoro E; Kocaata Z; Gabás-Rivera C; Comellas M; Prades M; Lizán L
Infect Dis Ther; 2023 Jan; 12(1):157-175. PubMed ID: 36367677
[TBL] [Abstract][Full Text] [Related]
14. Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.
Beusterien K; Maculaitis MC; Hallissey B; Gaschler MM; Smith ML; Law EH
Patient Prefer Adherence; 2021; 15():611-623. PubMed ID: 33776424
[TBL] [Abstract][Full Text] [Related]
15. Parental preferences for the procedural sedation of children in dentistry: a discrete choice experiment.
Zhuge J; Zheng D; Li X; Nie X; Liu J; Liu R
Front Pediatr; 2023; 11():1132413. PubMed ID: 38116578
[TBL] [Abstract][Full Text] [Related]
16. Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
Maculaitis MC; Liu X; Will O; Hanson M; McRoy L; Berk A; Crastnopol M
Patient Prefer Adherence; 2020; 14():2201-2214. PubMed ID: 33177814
[TBL] [Abstract][Full Text] [Related]
17. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.
González JM; Ogale S; Morlock R; Posner J; Hauber B; Sommer N; Grothey A
Cancer Manag Res; 2017; 9():149-158. PubMed ID: 28490902
[TBL] [Abstract][Full Text] [Related]
18. QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment.
Yin Y; Peng Q; Ma L; Dong Y; Sun Y; Xu S; Ding N; Liu X; Zhao M; Tang Y; Mei Z; Shao H; Yan D; Tang W
Qual Life Res; 2024 Mar; 33(3):753-765. PubMed ID: 38079024
[TBL] [Abstract][Full Text] [Related]
19. Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives.
Oliveri S; Lanzoni L; Veldwijk J; de Wit GA; Petrocchi S; Janssens R; Schoefs E; Smith MY; Smith I; Nackaerts K; Vandevelde M; Louis E; Decaluwé H; De Leyn P; Declerck H; Petrella F; Casiraghi M; Galli G; Garassino MC; Girvalaki C; Huys I; Pravettoni G
Front Psychol; 2023; 14():1062830. PubMed ID: 37425173
[TBL] [Abstract][Full Text] [Related]
20. A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice Experiment.
Liu F; Hu H; Wang J; Chen Y; Hui S; Hu M
Front Public Health; 2021; 9():653450. PubMed ID: 33842426
[No Abstract] [Full Text] [Related]
[Next] [New Search]